VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients
Launched by HARALD DOBNIG, MD · May 24, 2010
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Inclusion criteria
* Age ≥18 years
* expected ICU stay ≥48 hours
* vitamin D deficiency: 25(OH)D ≤ 20 ng/ml
* feasibility of study drug application via nasogastric tube in cases where oral food intake is not possible
Exclusion criteria
* moribund patient expected to die within 24 hours
* hypercalcaemia (total calcium \>2.65 OR ion. calcium \>1.35 mmol/l)
* severely impaired gastrointestinal motility (ileus, residual gastric volume \> 400 ml)
* known history of recent kidney stones (≤ 1 year)
* known granulomatous diseases (tuberculosis, sarcoidosis)
* pregnancy
Primary endpoint
* hospi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • expected ICU stay ≥48 hours
- • vitamin D deficiency: 25(OH)D ≤ 20 ng/ml
- • feasibility of study drug application via nasogastric tube in cases where oral food intake is not possible
- Exclusion Criteria:
- • moribund patient expected to die within 24 hours
- • hypercalcaemia (total calcium \>2.65 OR ion. calcium \>1.35 mmol/l)
- • severely impaired gastrointestinal motility (ileus, residual gastric volume \> 400 ml)
- • known history of recent kidney stones (≤ 1 year)
- • known granulomatous diseases (tuberculosis, sarcoidosis)
- • pregnancy
About Harald Dobnig, Md
Dr. Harald Dobnig, MD, is a distinguished clinical trial sponsor with extensive expertise in advancing medical research and innovation. With a strong background in clinical medicine and a commitment to improving patient outcomes, Dr. Dobnig leads initiatives that focus on the development and evaluation of novel therapeutic interventions. His collaborative approach fosters partnerships between academic institutions, healthcare providers, and industry stakeholders, ensuring rigorous study design and adherence to regulatory standards. Dr. Dobnig is dedicated to contributing to the scientific community through the successful execution of clinical trials that aim to translate research findings into meaningful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
Patients applied
Trial Officials
Harald Dobnig, MD
Principal Investigator
Medical University of Graz, Austria
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials